Modified Fe$\textsubscript{3}$O$_4$ Magnetic Nanoparticle Delivery of CpG Inhibits Tumor Growth and Spontaneous Pulmonary Metastases to Enhance Immunotherapy

Xueyan Zhang$^1$, Fengbo Wu$^2$, Ke Men$^1$, Rong Huang$^1$, Bailin Zhou$^1$, Rui Zhang$^1$, Rui Zou$^3$ and Li Yang$^1$*

Abstract
As a novel toll-like receptor 9 (TLR9) agonist, synthetic unmethylated cytosine-phosphate-guanine (CpG) oligodeoxynucleotides can stimulate a Th1 immune response and potentially be used as therapeutic agents or vaccine adjuvants for the treatment of cancer. However, some drawbacks of CpG limit their applications, such as rapid elimination by nuclease-mediated degradation and poor cellular uptake. Therefore, repeat high-dose drug administration is required for treatment. In this work, a CpG delivery system based on 3-aminopropyltriethoxysilane (APTES)-modified Fe$\textsubscript{3}$O$_4$ nanoparticles (FeNPs) was designed and studied for the first time to achieve better bioactivity of CpG. In our results, we designed FeNP-delivered CpG particles (FeNP/CpG) with a small average size of approximately 50 nm by loading CpG into FeNPs. The FeNP/CpG particle delivery system, with enhanced cell uptake of CpG in bone marrow-derived dendritic cells (BMDCs) in vitro and through intratumoral injection, showed significant antitumor ability by stimulating better humoral and cellular immune responses in C26 colon cancer and 4T1 breast cancer xenograft models in vivo over those of free CpG. Moreover, mice treated by FeNP/CpG particles had delayed tumor growth with an inhibitory rate as high as 94.4%. In addition, approximately 50% of the tumors in the C26 model appeared to regress completely. Similarly, there were lower pulmonary metastases and a 69% tumor inhibitory rate in the 4T1 breast cancer tumor model than those in the untreated controls. In addition to their effectiveness, the easy preparation, safety, and high stability of FeNP/CpG particles also make them an attractive antitumor immunotherapy.

Keywords: CpG, Magnetic nanoparticles, Intratumoral injection, Immunotherapy

Background
Malignant tumors are one of the major diseases threatening human health and life, and the incidence of tumors is continuously rising [1, 2]. Unfortunately, the outcomes of traditional treatments such as radiotherapy, chemotherapy, and surgery for malignant tumors have not been remarkably effective. In contrast to chemotherapy and radiotherapy, which target rapidly proliferating cells for death, immunotherapies are designed to enhance the host’s own immune defense system to target and eliminate tumor cells. It is noteworthy that immunotherapeutic CpG have been studied extensively for their efficacy in tumor prevention and regression [3]. Despite encouraging clinical data, the use of free CpG still has several disadvantages. First, CpG are susceptible to nuclease-mediated degradation under biological conditions. Second, they lack specificity to target cells after systemic administration and have poor cellular uptake. Therefore, improvements are likely to be required. Because TLR9s locate on endosomes, we hypothesized that the poor CpG uptake by tumor-associated inflammatory cells causes weak clinical response. Thus, methods that enhance CpG internalization might potentiate its immunostimulatory response.
Except for the drawbacks of free CpG, the route of administration of CpG affects the antitumor ability and toxicity. Free CpG and other stable phosphorothioate oligonucleotides administered by intravenous injection are cleared rapidly and have a broad tissue distribution [4, 5]. Furthermore, systemically administered free CpG can induce a nonspecific immune activation, leading to severe side effects, including immune cell exhaustion, destruction of lymphoid follicles, liver damage, and exacerbation of autoimmune diseases [6–8]. These properties may account for the failure of systemically administered free CpG in human patients [9]. Previous studies have demonstrated that the intratumoral injection of CpG had a great antitumor effect by “focusing” the immune stimulation on tumor sites [10]. How to control the retention time of CpG injected into tumor is a problem.

By using toll-like receptor-9, dendritic cells, macrophages, and NK cells can recognize CpG, which are common in bacterial DNA [11]. CpG induce immune cells to produce chemokines and cytokines, and the upregulated costimulatory cell surface molecules of T cell [12–15]. Thus, CpG have emerged as potent type 1-polarizing adjuvants [16, 17]. Moreover, injecting CpG directly into tumors is a form of immunization that uses the in situ tumor as a source of antigen and introduces CpG as an adjuvant to activate an immune response within the tumor. Therefore, we hypothesized that the intratumoral injection of CpG would abolish the immune privilege of tumors via recruiting and activating local dendritic cells, depending on the type 1 antitumor T cell response pathway.

To overcome the aforementioned problems, we developed a modified magnetic particle platform based on Fe3O4 particles to direct and control the release of CpG through intratumoral injection at tumor sites. Due to some unique characteristics of Fe3O4 magnetic particles, especially their good histocompatibility [18], superparamagnetism [19, 20], low toxicity [21], and easy preparation and targeted drug delivery with an external magnetic field [22, 23], their movement and concentration can be controlled in the body with an external magnetic field, allowing the Fe3O4 particles to be used as carriers of gene medicine with enhanced gene transfection efficiency [24]. In addition, coating APTES on Fe3O4 particles by covalent bonding prevents the formation of aggregates and offers more modification sites (amino groups) [25, 26] for further help in binding CpG. In this study, Fe3O4 magnetic particles were prepared by a co-precipitation method [27] and modified with APTES. CpG were firmly bonded to the surface of the modified Fe3O4 particles by electrostatic interaction to form FeNP/CpG particles with a diameter of approximately 50 nm. Further studies showed that FeNP particle delivery systems have an enhanced uptake efficiency of CpG compared to that of free CpG in dendritic cells, and the intratumoral injection of FeNP/CpG particles stimulates an effective antitumor Th1-type immune response not only to restrain the tumor in situ growth but also to inhibit tumor metastasis in C26 colon cancer and 4T1 breast cancer models in vivo. Therefore, nanopreparation therapy may be a potential tumor immunotherapy strategy.

**Materials and Methods**

**Materials and Animals**

3-Aminopropyltriethoxysilane (APTES) was obtained from Aladdin Company, Inc. Ferric chloride hexahydrate (FeCl3·6H2O) and ferrous chloride tetrahydrate (FeCl2·4H2O) were purchased from Tianjin Guangfu Fine Chemical Industry Research Institute. The following CpG was synthesized by Invitrogen Co.: 5′-TCGTGTTTTGTCGTTTTGTCG TT-3′. Fluorescein isothiocyanate (FITC) was purchased from Sigma-Aldrich (St Louis, MO, USA).

A human embryonic kidney cell line (293T), murine breast tumor cell line (4T1), and colon cancer cell line (C26) were obtained from American Type Culture Collection (ATCC), and bone marrow-derived dendritic cells (BMDCs) were obtained from BALB/c mice. Female 6–8-week-old BALB/c mice were purchased from Beijing HuaFuKang Laboratory Animal Co. Ltd. The mice were bred and kept under pathogen-free conditions. All animal protocols were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

**Preparation of FeNP**

The co-precipitation method was used for the synthesis of Fe3O4 particles [29]. In the experimental procedure, 11.68 g FeCl3·6H2O and 4.30 g FeCl2·4H2O were added into a three-necked flask containing 200 mL deionized water at 80 °C, followed by the addition of 15 ml 25% NH3·H2O. During the 1-h reaction process, the mixture was purged with N2 and stirred. Thirty milligrams of the prepared Fe3O4 was dispersed into a mixture of 60 ml deionized water, and absolute ethanol by ultrasonic vibration for 30 min. 0.3 g of prepared Fe3O4 was dispersed into a mixture of 4 ml deionized water and 600 mL absolute ethanol by ultrasonic vibration for 30 min. Then, 1.2 mL of APTES was added into the mixture under constant mechanical stirring for 7 h. The resulting functionalized APTES-modified Fe3O4 (FeNP) nanoparticles were magnetically separated from the supernatant by a magnet, then washed with ethanol and dried at 40 °C under vacuum for 24 h. Finally, the precipitate of the FeNP was prepared for further use.

**Characterization of FeNP/CpG Particles**

The particle size distribution spectra of Fe3O4, FeNP, and FeNP/CpG particles were determined using a Zetasizer Nano ZS90 laser particle size analyzer (Malvern...
In Vitro Transfection
BMDCs were prepared from BALB/c mice. Briefly, bone marrow cells from the femur and tibia were flushed out with free FBS-containing 1640 culture media using a syringe. Cells were centrifuged at 1500 rpm for 3 min, treated with ACK lysis buffer (Lonza Inc.) to remove red blood cells, and resuspended in RPMI-1640 culture medium containing 10% FBS in 96-well plates and grown for 24 h or 72 h. The prepared cells were exposed to a series of FeNP particles. The functionali-zed APTES-modified Fe$_3$O$_4$ particles (FeNP) was mixed with 1 µg CpG at different ratios (FeNP:CpG, w/w) in distilled water. After co-incubation for 30 min at room temperature, the mixtures electrophoresed on a 1% (w/v) agarose gel at 120 V for 30 min. The gel was then stained with Golden View™ (0.5 mg/mL) and photographed by a UV illuminator (Bio-Rad ChemiDoc XRS, USA).

In Vivo Tumor Inhibition Assay
One hundred thousand C26 or 4T1 cells were subcutaneously injected on the backs of each BALB/c mouse (6–8 weeks old). The volumes of the tumors were subsequently measured using a digital caliper and calculated by the following formula: tumor volume = 0.5 × length (mm) × width (mm)$^2$. On day 7, a particulate equivalent of 0.2 µg free FITC-conjugated CpG (CpG-FITC) or FeNP delivering CpG-FITC with a mass ratio of 10:1 was added to prede-signed wells. One or 3 h post-transfection, the growth media were removed, the cells were stained with DAPI for 10 min, and the cells were washed with physiological saline three times. Pictures of each well were taken with a laser scanning confocal microscope (LSCM), and the transfection efficiency was measured by flow cytometry (NovoCyte Flow Cytometer, ACEA Biosciences, USA).

In Vivo Tumor Inhibition Assay
One hundred thousand C26 or 4T1 cells were subcutaneously injected on the backs of each BALB/c mouse (6–8 weeks old). The volumes of the tumors were subsequently measured using a digital caliper and calculated by the following formula: tumor volume = 0.5 × length (mm) × width (mm)$^2$. Once the tumors reached approximately 50 mm$^3$ in size, the treatments were applied. The mice (n = 10) received either intratumoral injections of CpG/FeNP (at a ratio of 10:1) particulate equivalent to 20 µg CpG or CpG alone every 3 days for four treatments. Mice receiving an equivalent of normal saline (NS) or FeNP particles were regarded as control groups. The tumor size and animal body weight were monitored every 3 days. On day 31, all mice were sacrificed by cervical vertebra dislocation. The tumor size and other important organs were fixed with 4% neutral formalin followed by paraffin section for HE staining to evaluate the morphological difference and for immunofluorescence to test tumor microenvironments. In the 4T1 model, we measured tumor weight and counted the number of pulmonary metastasis nodules.

The tumor re-challenge experiment was processed in the C26 model. Briefly, mice cured with the FeNP/CpG treatment were re-challenged with 5 × 10$^5$ C26 or 4T1 cells s.c. into two separate sites on the opposite side of the flank without further treatment. Mice were sacrificed when the volume of the 4T1 tumor grew to 200–300 mm$^3$ or 20 days.

Cytotoxic T Lymphocytes Assay
The CTL assay was performed according to published methods. In detail, lymphocytes of the spleen as the effector cells were harvested and depleted of red cells with ammonium chloride and passed through nylon wool at the end of treatment experiments. 4T1 or C26 as target cells were labeled with 300 mci of Na$_{51}$CrO$_4$ for 2 h and then washed with PBS and dispensed into 96-well plates. The prepared effector cells were co-incubated with the target cells at different E:T ratios. The supernatants containing radioactivity from the target cells were measured with a scintillation counter. Specific lysis was determined as follows: % specific lysis = 100 [(release in the presence of CTL spontaneous release)/maximal release spontaneous release]$. In all experiments, the spontaneous release was less than 30% of the maximum release.

ELISpot Assay
Splenocytes were harvested from control or CpG-treated mice at the end of the experiment, and ELISpot assays were performed using the mouse IFN-γ/IL-4 Dual-Color
ELISpot kit according to the manufacturer’s instructions. The harvested splenocytes were co-incubated with their respective treatments for 96 h, the suspension was dropped, and the cells were washed with wash buffer three times before adding the mixed antibody of IFN-γ and IL-4. After being processed by chromogenic agents, the number of spot-forming cells (SFCs) was counted under a microscope.

**ELISA Assay**

An ELISA was performed to determine the levels of Ct-specific serum antibody titers according to the manufacturer’s instructions. In brief, micro-plates coated with purified whole Ct protein (BestBio Biotechnology Co. Shanghai, China) were rinsed with PBS solution containing 0.05% Tween 20 (PBST) and then blocked with 100 μl blocking buffer (5% skim milk in PBST) at 37 °C for 1 h. After being rinsed five times with PBST, the plates were incubated with immune sera (diluted at 1:1000 in blocking buffer, 100 μl/well) at 37 °C for 1 h. After being rinsed five times with PBST, the plates were incubated with HRP-conjugated goat anti-mouse IgG antibody (diluted at 1:2000 in blocking buffer, 100 μl/well) or vaginal washes (diluted at 1:10 in blocking buffer, 100 μl/well) at 37 °C for 2 h. After being rinsed five times with PBST, the plates were incubated with HRP-conjugated goat anti-mouse IgA antibody (diluted at 1:1000 in blocking buffer, 100 μl/well) or HRP-conjugated goat anti-mouse IgA antibody (diluted at 1:2000 in blocking buffer, 100 μl/well) at 37 °C for 1 h.

**Histological Analysis**

The tumor tissue and major organs harvested from in vivo inhibition studies were fixed and embedded in paraffin. After dewaxing and rehydrating, wax-embedded tissue sections were staining with Mayer’s HE. To analyze infiltrating lymphocytes (TILs) within the tumor tissues from each group, sections were subjected to high-pressure antigen repair, stained with anti-mouse FITC-CD4, PE-CD8, and PE-CD49b (as NK maker) (BD, USA) for 1 h at 4 °C, and then stained with DAPI for 10 min prior to PBS washing for imaging. An image from each group was taken through a positive fluorescence microscope (Olympus, Japan).

**Statistical Analysis**

Data were expressed as the mean value ± standard deviation. Statistical analysis was performed with a one-way analysis of variance (ANOVA) using Prism 5.0c Software (GraphPad Software, La Jolla, CA, USA) SPSS 17 software. An inter-group comparison was performed using Tukey’s test for the single-factor analysis of variance (ANOVA). P values < 0.05 were considered statistically significant.

**Results**

**Preparation and Characterization of FeNP/CpG Particles**

To develop a magnetic particle for CpG delivery with low cytotoxicity, Fe$_3$O$_4$ particles were synthesized using the co-precipitation method as shown in Fig. 1a. Grafting the aminopropylsilane groups (–O)3Si–CH2–CH2–NH2 of APTES on the surface of Fe$_3$O$_4$ to form FeNP particles (Fig. 1b). Negatively charged CpG (CpG) bind to effective functional groups provided by the APTES to form FeNP/CpG particles through electrostatic interactions as schematically represented in Fig. 1c. Based on the dynamic light scattering measurement, the size of the prepared Fe$_3$O$_4$ particles was 10.7 ± 4.1 nm (Fig. 2a). As observed through TEM (Fig. 2b) and SEM (Fig. 2c), Fe$_3$O$_4$ developed in this work displayed a uniform and near-spherical shape. The dynamic diameter of APTES-modified Fe$_3$O$_4$ particles was 34.5 ± 5.0 nm (Fig. 2d), which was in good agreement with the TEM results (Fig. 2e).

To illustrate the binding ability of FeNP particles to CpG, a gel retarding assay was performed (Fig. 2f). When the molar ratio of FeNP with CpG was 10:1, no bright CpG band was observed, showing the negatively charged CpG can be completely adsorbed by FeNP particles through electrostatic interactions after electrophoresis. Therefore, we chose that prescription ratio for further application in our study. Together, these results demonstrated that CpG can combine successfully on the surface of FeNPs through electrostatic interactions, showing stability and a small dimension.

**Cell Viability and Transfection of FeNP/CpG Particles In Vitro**

To further describe the biophysical characterization in vitro, we detected the cytotoxicity of FeNPs in 293T, 4T1, and C26 cells at the point of 24 h or 72 h (Fig. 3a). There was no obvious dose-dependent relationship between the cell viability and FeNP particles in the 293T, C26, and 4T1 cells. The cell survival rate was more than 80% at 24 h and 60% at 72 h on three kinds of cells, even at a FeNP concentration of 1.25 mg/ml. These results proved the biocompatibility of FeNP particles whether for normal cells (293T) or tumor cells (C26, 4T1).

Dendritic cells as major receptor cells for CpG play an important role in an antitumor immune response mediated by TLR9. CpG as a potent type 1-polarizing adjuvant induces DCs to activate an immune response within the tumor by secreting chemokines and cytokines. Therefore, the efficient delivery of CpG into DC cells is crucial to achieve an antitumor response. In our study, FITC-conjugated CpG were used to investigate the delivery ability of FeNP particles to DCs in vitro. After 1- or 3-h post-transfection, via laser scanning confocal microscopy (LSCM), the cellular fluorescence intensity in the FITC-conjugated CpG-coated FeNP particle (FeNP/CpG-FITC)-treated groups was higher than that for the equivalent amount of free CpG groups (Fig. 3b). The FeNP/CpG-FITC particles were able to transfact up to 18.3% of the DCs after 1 h. Then, 3 h post-transfection, the ratio of the positive cells increased
FeNPs Deliver CpG to Xenograft and Inhibit Tumor Growth and Spontaneous Pulmonary Metastases In Vivo

The anticancer activity of CpG/FeNP particles was first evaluated in C26 colon cancer and 4T1 breast cancer subcutaneous transplantation tumor models in vivo. When the tumor volume was approximately 50 mm³, mice were randomly divided into four groups to start treatment ($n = 10$). Mice were treated with an intratumoral injection of CpG/FeNP particles three times throughout the entire experiment (Fig. 4a). In our study, intratumoral injection of FeNP/CpG particles resulted in a significant inhibition of xenograft tumor growth compared with that of the control groups, and the inhibitory rate was up to 69% ($P < 0.05$ versus NS) (Fig. 4b). Compared with the normal saline (NS) treatment group (0.90 ± 0.08 g) and the FeNP group (0.81 ± 0.03 g), the FeNP/CpG particle-treated groups experienced a statistically significant reduction in tumor weight (0.38 ± 0.03 g, $P < 0.001$). Comparatively, the free CpG group showed minimal anticancer ability (0.68 ± 0.03 g) (Fig. 4c). In addition, mice in the PBS control group developed extensive pulmonary metastases, in comparison, those treated with the FeNP/CpG particles showed a 64.1% decrease in the number of tumor nodules in the lung (Fig. 4d, e), demonstrating the power of the FeNP/CpG particles in treating metastatic tumors. As shown in Fig. 4f, H&E staining of the lung showed reduced lung burden with clearly pulmonary metastases after FeNP/CpG treatment than other groups. These results indicate that FeNP
delivery CpG into 4T1 cells not only significantly inhibited 4T1 tumor growth \( (P < 0.001 \text{ versus NS}) \) but also suppressed the metastasis of breast cancer to the lungs.

Similarly, a significant enhanced antitumor effect with FeNP/CpG treatment groups was observed in the subcutaneous model of C26-incubated mice. As shown in Fig. 4g, the tumor grew rapidly in the control mice, vehicle group, and CpG group, with mean tumor volumes of approximately 2300 ± 239.4 mm\(^3\), 2116.7 ± 360.9 mm\(^3\), and 1353.3 ± 158.9 mm\(^3\), respectively, by day 31. In contrast, in the FeNP/CpG group, the tumor growth was extremely inhibited, with a mean tumor volume of approximately 153.7 ± 62.7 mm\(^3\) (\( P < 0.01 \text{ versus NS} \)) and an inhibitory rate of 94.4%. The tumors seemed to grow slowly after the initial treatment, and a part of the tumors begin to disappear gradually after the end of the three treatments. Even more importantly, in the FeNP/CpG particle treatment groups, the tumors in nearly half of the mice completely had disappeared by the end of the experiment. As shown in Fig. 4h, the FeNP/CpG treatment group had a much lower average tumor weight than that of the other groups (\( P < 0.001 \)): FeNP/CpG treatment group (0.14 ± 0.08 g), NS group (2.41 ± 0.26 g), FeNP group (2.50 ± 0.4 g), and CpG group (1.44 ± 0.32 g). To determine whether FeNP/CpG particles were sufficient to mediate the specific antitumor response, a tumor re-challenge experiment was processed in the C26 model (Fig. 4i). The mice whose tumors were completely regressive after the FeNP/CpG particle treatment in the C26 colon cancer model were inoculated with 4T1 and C26 tumors in different positions on the BALB/c mice subcutaneously, and no further treatment was given. All the 4T1 tumors grew rapidly, and their volumes surpassed 1000 mm\(^3\) by day 20 post-challenge. In contrast, there were solid tumors that were invisible to the naked eye in the C26 model, suggesting the FeNP/CpG particles groups stimulated a specific antitumor response. These results suggested that the intratumoral injection of FeNP/CpG particles efficiently inhibited the growth of a subcutaneous xenograft.

**FeNP/CpG Particles Stimulate Enhanced Systematic Antitumor Immune Response**

The in vivo antitumor mechanisms of FeNP/CpG particles in the above two models were further studied. To study the
type of immune response, we applied the ELISpot assay to analyze the IFN-γ/IL-4 levels of the mouse spleen. If the IFN-γ level in spleen lymphocytes (showing erythema on the ELISpot board) is significantly more than the IL-4 level (showing blue spots in ELISpot board), the type of immune response stimulated was Th1, namely, to activate CD8+ T lymphocytes and mainly the body’s CTL response. Otherwise, the type of immune response was Th2, namely, to mainly activate CD4+ T lymphocytes, thus stimulating B lymphocytes and producing antigen-specific antibodies. A dual-color ELISpot assay was conducted to measure the expression of IFN-γ and IL-4 in different treatments (Fig. 5a).

Compared with that in the other three groups, the number of spot-forming cells (SFCs) of IL-4 and IFN-γ secreted from mice spleen lymphocytes had an ascending trend in the FeNP/CpG particle treatment group, and the number of SFCs secreting IFN-γ was 1.5-fold greater than that for IL-4 ($P < 0.05$), which implied an enhanced antitumor cellular immune response after FeNP/CpG particle intratumoral injection. In addition, the serum from the NS, FeNP, CpG, and FeNP/CpG-treated mice was analyzed using an ELISA assay for the presence of total tumor-specific IgG after three immunizations. In the C26 tumor model, although FeNP/CpG-immunized mice developed significantly higher titers of tumor-specific IgG than those in other groups (Fig. 5b), there was no statistical difference between FeNP/CpG-immunized mice and CpG-immunized mice.

To assess the cell-mediated immune response stimulated by the FeNP/CpG, CTL activity was assessed using the 51Cr release assay on C26 and 4T1 cells ex vivo.
When the killing activity of CTL was at a 100:1 ratio of effector cells to target cells, in the C26 cells, the effectors in the FeNP/CpG groups showed 8.2-fold more tumor-killing activity than that in the NS group and 9.7-fold and 1.7-fold more than that in the FeNP and CpG groups ($P < 0.05$ versus NS) (Fig. 5c). Similarly, this observation was coincident with the result in the 4T1 cells; the FeNP/CpG group had 7.4-fold more tumor-killing activity than that of the NS group and 6.6-fold and 1.4-fold more than that of the FeNP and CpG groups ($P < 0.05$ versus NS) (Fig. 5c).
CpG groups ($P < 0.01$ versus NS). These results illustrated that compared to that of free CpG, the use of APTES-coated Fe$_3$O$_4$ to deliver CpG can stimulate a more intense humoral immune response and result in a better antitumor efficiency in vivo.

The FeNP/CpG Increases Infiltrating Lymphocytes in Tumors and Alters Tumor Microenvironments

Tumor-infiltrating lymphocytes (TILs), a primary immune component infiltrating solid tumors, are considered the manifestation of the host antitumor reaction. Immunofluorescence analyses were performed to study TILs in tumors. The intensity of infiltration by CD4$^+$ T cells, CD8$^+$ T cells and CD49B$^+$ NK cells was studied (Fig. 5d). There was a significant increase in the intensity of infiltration of NK cells, CD4$^+$ T cells, and CD8$^+$ T cells in tumors from the FeNP/CpG groups compared with that in the FeNP, CpG, and NS groups ($P < 0.005$), which suggests that FeNP/CpG not only stimulates a higher immune response but also alters the tumor microenvironment by activating more immune cells into the tumor tissues. During the entire experiment, the mouse body weight and state were observed, and there was no piloerection, poor appetite, weight loss, or abnormal behavior in the C26 xenograft model (Fig. 6a). As shown in Fig. 6b, no significant pathological changes in heart, liver, spleen, lung, or kidney were observed through HE analysis. No histopathological changes and changes of body weight were observed in the 4T1 subcutaneous xenograft model (data not shown). Overall, our data suggested that the developed FeNP particles for CpG delivery were capable of treating cancer and inhibiting tumor metastasis with high safety.
Discussion

Synthetic CpG, identified as an effective drug in immunotherapy by simulating the immune activation of natural bacterial DNA [28–30], have been characterized in a variety of tumor models. CpG intratumoral injection is one of treatments in clinical trials on CpG. Molenkamp and his colleagues showed that the intratumoral injection of CpG alone or combined with radiotherapy could obviously increase the tumor-specific CD8+ T cell immune response in lymphoma or melanoma patients, causing systemic tumor regression [31]. So far, CpG combined with other treatments showed both a great antitumor effect and good security, which suggests that CpG are quite effective in tumor immunotherapy. However, the greater challenge of CpG truly coming into clinical application is if they can efficiently be delivered into the cells to combine with receptors such as TLR9 to stimulate an immune response. Nanotechnology can address such concerns by enhancing the delivery of CpG to antigen-presenting cells, and a number of nanocarriers have been explored for this purpose [32–34]. The nanoparticle formulations explored include gelatin particles, liposomes [35, 36], and DNA origami structures, but these were only explored in the context of combination treatments.

In this study, we first developed a non-viral delivery system, FeNPs, which were easily formed via APTES-modified Fe3O4 to deliver CpG into BMDCs. The CpG surrounded the surface of the modified magnetic Fe3O4 particles via electrostatic interactions to form FeNP/CpG particles with a small size distribution. The FeNP/CpG particles not only showed enhanced transfection efficiency compared to that of free CpG but also had a great antitumor effect in subcutaneous tumor models of C26 colon cancer, with 94.5% tumor inhibition, and 4T1 breast cancer, with a 64.3% inhibitory rate, though intratumoral injection in vivo. Moreover, FeNP/CpG treatments significantly stimulate an effective antitumor immune response and alter the tumor microenvironment by recruiting a number of immune cells to tumor tissues.

We further discuss possible reasons to account for the enhanced transfection and therapeutic efficiency of FeNP/CpG particles over that of free CpG. First, the developed FeNPs take advantage of characteristics such as their good histocompatibility, superparamagnetism, and a strong positive charge (for the Fe3O4 particles) to assist in delivering the CpG into the intracellular space, resulting in drug-carrier particles focusing on the tumor site to increase the drug concentrations in the area, reduce the drug loss, and improve drug utilization. Simultaneously, APTES was used to modify Fe3O4, providing more CpG binding sites to firmly bind the CpG onto the carrier. FeNPs exerted higher cell viability on 293T, C26, and 4T1 cells in vitro, and there was no remarkable pathological change after FeNP/CpG treatment by intratumoral injection that could avoid the side effects due to CpG entering into circulation by systemic administration. Second, the FeNP load CpG into DCs with a higher transfection efficiency than that of free CpG, increasing opportunities for integration with intracellular TLR9, which is widely expressed in macrophages, NK cells, DCs, and so on. The combination of CpG and TLR9 induces the secretion of local cytokines and chemokines, recruiting and activating immune cells of the innate immune response to stimulate the antitumor immune response; additionally, NK cells and CTLs could kill tumor cells directly or use IFN-γ or granzyme B to kill tumor cells [37, 38]. We suspected that FeNP/CpG may be taken up by the recruited immune cells to trigger the secondary cascade amplification of the immune response. Third, some studies have indicated that CpG can react with tumor cells expressing TLR9, aiming to induce tumor cell autophagy [39]. Autophagy may
enhance the sensitivity of tumor cells to the immune response, and the ATP dependent on autophagy could be released extracellularly and used to recruit DCs into the tumor tissue, activating the tumor-specific T cell immune response. This therapy is a form of immunization that uses the in situ tumor as a source of antigen and introduces CpG as an adjuvant to activate an immune response within the tumor. In our study, although the FeNP/CpG was injected without any specific tumor antigen, a cell-specific and systematic immune response could be elicited, and the contralateral tumors appear regressive, as shown in the tumor re-challenge experiment and the two-tumor site model. In addition, being coated with the lysate of tumor cells in a 96-well plate, the ELISA assay showed after FeNP/CpG intratumoral injection in mice that the antitumor antibody titer in the serum appeared to significantly increase. The ELISpot assay suggested that FeNP/CpG treatment, to a great degree, increased the spleen lymphocyte secretion of IFN-γ and IL-4, especially that of IFN-γ, which indicated that the humoral immunity responses and cellular immunity responses were both enhanced by treatment with FeNP/CpG in mice. In addition, immunohistochemistry analyses were performed to study TILs in the tumor microenvironment. Compared to that in the other groups, in the FeNP/CpG group, the number of CD4+ T, CD8+ T, and NK cells in the tumors showed a significant increase. Taken together, our study suggested that FeNP/CpG particle intratumoral injection may be a potential tumor immunotherapy strategy.

In recent years, treatment strategies based on nucleic acids have become one of the important areas of tumor treatment. The negative charge of the lipid bilayer of cell membranes makes it difficult for nucleic acid drugs with the same charge to pass through the cell membrane into the cell. Thus, APTES-modified Fe3O4 as a safe and efficient delivery system is expected to be used for other nucleic acid drugs to contribute to the carrier solution.

**Conclusion**

In summary, magnetic APTES-modified Fe3O4 particles (FeNP) were used to deliver CpG adjuvants via intratumoral injection to treat C26 colon carcinoma and 4T1 breast cancer, with enhanced antitumor ability over that of free CpG. The prepared FeNPs showed high stability, low toxicity, and high transfection ability for CpG in vitro and in vivo. Our results demonstrated the potential capacity of FeNP particles in non-viral nucleic acid drug delivery and offered an alternative strategy for CpG immunotherapy.

**Abbreviations**

APTES: 3-Aminopropyltriethoxysilane; BMDC: Bone marrow-derived dendritic cell; CpG: Cytosine-phosphatase-guanine; CpG-FITC: FITC-conjugated CpG; FeNP: 3-Aminopropyltriethoxysilane-modified Fe3O4 nanoparticle; FeNP/CpG: FeNP-delivered CpG particles; FeNP/CpG-FITC: FeNP-delivered CpG-FITC particles; GM-CSF: Granulocyte-macrophage colony-stimulating factor

**Funding**

This study was supported by the National Natural Science Foundation of China (No. 31570927) and the Technology Research and Development Program of Sichuan Province (No. 2015SZ0013).

**Availability of Data and Materials**

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ Contributions**

All authors contributed toward the data analysis and drafting and revising the paper and agree to be accountable for all aspects of the work.

**Ethics Approval**

All our animal-handling procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and followed the guidelines of the Animal Welfare Act.

**Competing Interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. 2Department of Pharmacy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China. 3China West Normal University, No.1 Shi Da Road, Nanchong 637002, China.

Received: 20 June 2018 Accepted: 6 August 2018
Published online: 17 August 2018

**References**

1. Goss PE, Strasser-Weippl K et al (2014) Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 15(5):489–538
2. Umar A, Dunn BK, Greenwald P (2012) Future directions in cancer prevention. Nat Rev Cancer 12:835–848
3. Maurer T, Pournaras C et al (2013) Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses. Urol Oncol 31(7):1395–1401
4. Link BK, Ballas ZK, Weisford D et al (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother 29(5):558–568
5. Bode C, Zhao G et al (2011) CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10:499–511
6. Hanagata N (2012) Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine 7: 2181–2195
7. Milley B, Kiwan R (2016) Optimization, production and characterization of a CpG oligonucleotide-Ficoll conjugate nanoparticle adjuvant for enhanced immunogenicity of anthrax protective antigen. Bioconjug Chem 27(5):1293–1304
8. Heikenwalder M, Polymenidou M, Junt T et al (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10(2):187–192
9. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CpG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 27(6):460–471
10. Lou Y, Liu C, Lizee G et al (2011) Anti-activity mediated by CpG: the route of administration is critical. J Immunother 34(3):279–288
11. Ohno U, Shibata T et al (2015) Structural basis of CpG and inhibitory DNA recognition by toll-like receptor 9. Nature 520(7549):702–705
12. Kalekar LA, Schmieg SE et al (2016) CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors. Nat Immunol 17(3):304–314
13. Soema PC, Rosendahl Huber SK et al (2015) Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine. Pharm Res 32(4):1505–1515
14. Komori HK, Hart T et al (2015) Defining CD4 T cell memory by the epigenetic landscape of CpG DNA methylation. J Immunol 194(4):1565–1579
15. Kataoka K, Nagata Y et al (2015) Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet 47(11):1304–1315
16. Julier Z, de Titta A et al (2016) Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine 34(21):2453–2469
17. Shirot A, Tross D, Klinman DM (2015) CpG oligonucleotides as cancer vaccine adjuvants. Vaccines (Basel) 3(2):390–407
18. Wang J, Zhao G et al (2016) Magnetic induction heating of superparamagnetic nanoparticles during rewarming augments the recovery of HUCM-MSCs cryopreserved by vitrification. Acta Biomater 33:264–274
19. Ta’i Y, Wang L, Yan G, Gao J-m, Yu H, Zhang L (2011) Recent research progress on the preparation and application of magnetic nanospheres. Polym Int 60(7):976–994
20. Semkina A, Abakumova M et al (2015) Core–shell–corona doxorubicin-loaded superparamagnetic Fe3O4 nanoparticles for cancer theranostics. Colloids Surf B: Biointerfaces 136:1073–1080
21. Asfaram A, Ghadi M et al (2017) Rapid ultrasound-assisted magnetic microextraction of gallic acid from urine, plasma and water samples by HKUST-1-MOF-Fe3O4-GA-MIP-NPs: UV–vis detection and optimization study. Ultrason Sonochem 34:561–570
22. Zhang Q, Luan L, Feng S, Yan H, Liu K (2012) Using a bifunctional polymer for the functionalization of Fe3O4 nanoparticles. React Funct Polym 72(3):198–205
23. Rainer T, Stefan L, Stephan D et al (2013) Efficient drug-delivery using magnetic nanoparticles-biodistribution and therapeutic effects in tumour bearing rabbits. Nanomedicine 9(7):961–971
24. Kami D, Takeda S, Itakura Y, Gojo S, Watanabe M, Toyoda M (2011) Application of magnetic nanoparticles to gene delivery. Int J Mol Sci 12(6):3705–3722
25. Long J, Li X et al (2015) Immobilization of pullulanase onto activated magnetic chitosan/Fe3O4 nanoparticles prepared by in situ mineralization and effect of surface functional groups on the stability. Colloids Surf A Physicochem Eng Asp 472:69–77
26. Safi B, Wang C et al (2015) Synthesis and characterization of Fe3O4 coated on APTES as carriers for morin-anticancer drug. J Biomater Nanobiotechnol 6:267–275
27. Liu X, Ma Z, Xing J, Liu H (2004) Preparation and characterization of amino-silane modified superparamagnetic silica nanospheres. J Magn Magn Mater 270(1–2):1–4
28. Gungor B, Yagci FC, Tincer G et al (2014) CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity. Sci Transl Med 6:233ra61
29. Lin AT, Almeida JP, Bear A et al (2013) Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One 8(5):e63550
30. Wang X, Wang L, Wan M et al (2013) Fully phosphorothioate-modified CpG ODN with polyg motif inhibits the adhesion of B16 melanoma cells in vitro and tumorgenesis in vivo. Nucleic Acid Ther 23(4):253–263
31. Cittinden M, Koh K H et al (2015) Current clinical trials testing combinations of immunotherapy and radiation. Radiation Oncology 25:54–64
32. Schüller VJ, Heidegger S, Sandhober N et al (2011) Cellular immunostimulation by CpG-sequence-coated DNA origami structures. ACS Nano 5(12):9696–9702
33. Schüller S, Wissgroll L et al (2016) The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells. Pediatr Res 80:311–318
34. Lee I-H, Kwon H-K, An S et al (2012) Ineagable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew Chem Int Ed Engl 51(35):8800–8805
35. Kraft JC, Freeling JP et al (2014) Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 103(1):29–52
36. Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951
37. Shirot A, Shirot H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188(4):1592–1599
38. Hanagata N (2017) CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies. Int J Nanomedicine 12:515–531
39. Eiro N, Gonzalez L, Gonzalez LO et al (2012) Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer. J Clin Immunol 32(4):848–854